RxSight, Inc. raised earnings guidance for the full year of 2023. For the year, company expects Revenue of $85.0 million to $87.0 million, representing implied growth of 73% to 78% compared to 2022, up from prior guidance of $81.0 million to $86.0 million and Gross margin in the range of 60% to 61%, representing an implied increase of 36% to 39% compared to 2022, up from prior guidance of 58% to 60%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
60.96 USD | -0.31% | -2.25% | +51.19% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+51.19% | 2.38B | |
-7.38% | 177B | |
-0.46% | 108B | |
-6.98% | 65.55B | |
+2.65% | 50.66B | |
+5.27% | 42.58B | |
+5.73% | 40.74B | |
+19.92% | 31.07B | |
+16.57% | 25.45B | |
-7.00% | 23.85B |
- Stock Market
- Equities
- RXST Stock
- News RxSight, Inc.
- Rxsight, Inc. Raises Earnings Guidance for the Full Year of 2023